Identification of NVP-BKM120 as a potent, selective, orally bioavailable class i PI3 kinase inhibitor for treating cancer

ACS Medicinal Chemistry Letters

Volumn 2, Issue 10, 2011, Pages 774-779

  Burger, Matthew T ^a   Pecchi, Sabina ^a   Wagman, Allan ^a   Ni, Zhi Jie ^a   Knapp, Mark ^a   Hendrickson, Thomas ^a   Atallah, Gordana ^a   Pfister, Keith ^a   Zhang, Yanchen ^a   Bartulis, Sarah ^a   Frazier, Kelly ^a   Ng, Simon ^a   Smith, Aaron ^a   Verhagen, Joelle ^a   Haznedar, Joshua ^a   Huh, Kay ^a   Iwanowicz, Ed ^a   Xin, Xiaohua ^a   Menezes, Daniel ^a   Merritt, Hanne ^a   Lee, Isabelle ^a   Wiesmann, Marion ^a   Kaufman, Susan ^a   Crawford, Kenneth ^a   Chin, Michael ^a   Bussiere, Dirksen ^a   Shoemaker, Kevin ^a   Zaror, Isabel ^a   Maira, Sauveur Michel ^a   Voliva, Charles F ^a   more..

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

NVP BKM120; phosphoinositide 3 kinase; PI3K AKT3 pathway

Indexed keywords

AMINOPYRIDINE; NVP BKM 120; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CANCER THERAPY; CELL ACTIVITY; CELL PROLIFERATION; CRYSTAL STRUCTURE; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENCY; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 80054737055     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml200156t     Document Type: Article

References (19)

1. Engelman, J. A.; Luo, J.; Cantley, L. C. The Evolution of Phosphatidylinositol 3-Kinases as Regulators of Growth and Metabolism Nat. Rev. Genet. 2006, 7, 606-619 (Pubitemid 44100518)
2. Katso, R.; Okkenhaug, K.; Ahmadi, K.; White, S.; Timms, J. Cellular Function of Phosphoinositide 3-Kinases: Implications for Development, Homeostasis and Cancer Annu. Rev. Cell Dev. Biol. 2000, 17, 615-675 (Pubitemid 33096187)
3. Samuels, Y.; Wang, Z.; Bardelli, A.; Silliman, N.; Ptak, J.; Szabo, S.; Yan, H.; Gasdar, A.; Powell, S. M.; Riggins, G. J.; Willson, J. K.; Markowitz, S.; Kinzler, K. W.; Vogelstein, B.; Velculescu, V. E. High Frequency of Mutations of the PIK3CA Gene in Human Cancers Science 2004, 304, 554 (Pubitemid 38541907)
4. Leslie, N. R.; Downes, C. P. PTEN Function: How Normal Cells Control it and Tumour Cells Lose it Biochem. J. 2004, 382, 1-11 (Pubitemid 39141560)
5. Liu, P.; Cheng, H.; Roberts, T. M.; Zhao, J. J. Targeting the Phosphoinositide 3-Kinase Pathway in Cancer Nat. Rev. Drug Discovery 2009, 8, 627-644
6. Nuss, J. M.; Tsuhako, A. L.; Anand, N. K. Emerging Therapies Based on Inhibitors of Phosphatidyl-Inositol-3-Kinases. In Annual Reports in Medicinal Chemistry; Macor, J. E., Ed.; Academic Press: Oxford, 2009; Vol. 44, pp 339-351.
7. Maira, S.-M.; Stauffer, F.; Brueggen, J.; Furet, P.; Schnell, C.; Fritsch, C.; Brachmann, S.; Chene, P.; De Pover, A.; Schoemaker, K.; Fabbro, D.; Gabriel, D.; Simonen, M.; Murphy, L.; Finan, P.; Sellers, W.; Garcia-Echeverria, C. Identification and Characterization of NVP-BEZ235, a New Orally Available Dual Phosphatidylinositol 3-kinase/Mammalian Target of Rapamycin Inhibitor with Potent in Vivo Antitumor Activity Mol. Cancer Ther. 2008, 7, 1851-1863
8. Folkes, A. J.; Ahmadi, K.; Alderton, W. K.; Alix, S.; Baker, S. J.; Box, G.; Chuckowree, I. S.; Clarke, P. A.; Depledge, P.; Eccles, S. A.; Friedman, L. S.; Hayes, A.; Hancox, T. C.; Kugendradas, A.; Lensun, L.; Moore, P.; Olivero, A. G.; Pang, J.; Patel, S.; Pergl-Wilson, G. H.; Raynaud, F. I.; Robson, A.; Saghir, N.; Salphati, L.; Sohal, S.; Ultsch, M. H.; Valenti, M.; Wallweber, H. J. A.; Wan, N. C.; Wiesmann, C.; Workman, P.; Zhyvoloup, A.; Zvelebil, M. J.; Shuttleworth, S. J. The Identification of 2-(1H-Indazol-4-yl)-6-(4- methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer J. Med. Chem. 2008, 51, 5522-5532
9. Knight, S. D.; Adams, N. D.; Burgess, J. L.; Chaudhari, A. M.; Darcy, M. G.; Donatelli, C. A.; Luengo, J. E.; Newlander, K. A.; Parrish, C. A.; Ridgers, L. H.; Sarpong, M. A.; Schmidt, S. J.; Van Aller, G. S.; Carson, J. D.; Diamond, M. A.; Elkins, P. A.; Gardiner, C. M.; Garver, E.; Gilbert, S. A.; Gontarek, R. R.; Jackson, J. R.; Kershner, K. L.; Luo, L.; Raha, K.; Sherk, C. S.; Sung, C. M.; Sutton, D.; Tummino, P. J.; Wegrzyn, R. J.; Auger, K. R.; Dhanak, D. Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin ACS Med. Chem. Lett. 2010, 1, 39-43
10. Courtney, K. D.; Corcoran, R. B.; Engelman, J. A. The PI3K Pathway as Drug Target in Human Cancer J. Clin. Oncol. 2010, 28, 1075-1083
11. Pecchi, S.; Renhowe, P. A.; Taylor, C.; Kaufman, S.; Merrit, H.; Wiesmann, M.; Shoemaker, K.; Knapp, M. S.; Hendrickson, T. F.; Fantl, W.; Voliva, C. F. Identification and Structure-Activity Relationship of 2-Morpholino 6-(3-hydroxyphenyl)pyrimidines, a Class of Potent and Selective PI3-kinase Inhibitors Bioorg. Med. Chem. Lett. 2010, 20, 6895-6898
12. Burger, M. T.; Knapp, M.; Wagman, A.; Ni, Z. J.; Hendrickson, T.; Atallah, G.; Zhang, Y.; Frazier, K.; Verhagen, J.; Pfister, K.; Ng, S.; Smith, A.; Bartulis, S.; Merrit, H.; Wiesmann, M.; Xin, X.; Haznedar, J.; Voliva, C. F.; Iwanowicz, E.; Pecchi, S. Synthesis and in Vitro and in Vivo Evaluation of Phosphoinositide-3-kinase Inhibitors ACS Med. Chem. Lett. 2011, 2, 34-38
13. By mimicking the electronics and H bond donating capabilities of the aminopyrimidines. see: Mautner, M. Models for Strong Interactions in Proteins and Enzymes. 1. Enhanced Acidities of Principal Biological Hydrogen Donors J. Am. Chem. Soc. 1988, 110, 3071-3075
14. Walker, E. H.; Pacold, M. E.; Perisic, O.; Stephens, L.; Hawkins, P. T.; Wymann, M. P.; Roger, L. Structural Determinants of Phosphoinositide-3-Kinase Inhibition by Wortmannin, LY294002, Quercetin, Myricetin and Staurosporine Mol. Cell 2000, 6, 909-919
15. Knight, Z. A.; Chiang, G. G.; Alaimo, P. G.; Kenski, D. M.; Ho, C. B.; Coan, K.; Abraham, R. T.; Shokat, K. M. Isoform Specific Phosphoinositide-3- Kinase Inhibitors from an Arylmorpholine Scaffold Bioorg. Med. Chem. 2004, 12, 4749-4759 (Pubitemid 39044362)
16. "NVP-BKM120, a novel inhibitor of phosphoinositide 3-kinase in Phase I/II clinical trials, shows significant antitumor activity in xenograft models". Maira, M.; Menezes, D.; Pecchi, S.; Shoemaker, K.; Burger, M.; Schnell, C.; Fritsch, C.; Brachmann, S.; Nagel, T.; Sellers, W. R.; Garcia-Echeverria, C.; Wiesmann, M.; Voliva, C. F. 2010 AACR annual meeting, Washington, D.C., Abstract 4497.
17. "Oral Pan-Class I PI3K Inhibitor BKM120 Monotherapy in Patients with Advanced Solid Tumors: an Update on Safety and Efficacy". Graña-Suárez, B.; Burris, H. A.; Anhert, J. R.; Abdul Razak, A. R.; De Jonge, M. J.; Eskens, F.; Siu, L. L.; Ru, Q. C.; Homji, N. F.; Demanse, D.; Di Tomaso, E.; Cosaert, J.; Quadt, C.; Baselga, J.; Bendell, J. C. 47th ASCO Annual Meeting, June 2001, Chicago, IL, Abstract 3043.
18. Novartis internal data.
19. www.clinicaltrials.gov and NVP-BKM120.